HomeNewsBusinessCoronavirus impact | SaaS firms may see 10% drop in revenue, delay in new deals

Coronavirus impact | SaaS firms may see 10% drop in revenue, delay in new deals

Major transformation deals, where SaaS firms play a major role, are likely to be suspended now and the existing contracts may be delayed

March 19, 2020 / 14:25 IST
Story continues below Advertisement

India-based Software-as-a-Service (SaaS) startup expect 10-25 percent drop in revenue and deal deferrals as the Novel Coronavirus, or COVID-19, pandemic continues to spread across the world, impacting business operations.

Suresh Sambandam, CEO, KiSSFLOW, a workplace automation software, said the industry may see a 10 percent revenue hit in the short term, which may rise to 25 percent since it is impacting global firms.

Story continues below Advertisement

A recent NASSCOM report pegs the Indian SaaS market at $3.3-3.4 billion in 2020.

How are SaaS firms impacted? Most revenues for Indian SaaS players come from overseas, primarily the US. Due to COVID-19, major businesses are disrupted, in turn affecting their service providers, including SaaS firms.

Also, IT spends are discretionary. As firms clampdown on spending and minimise cost, discretionary spending will see a cut.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show